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under the CC BY license (http://creaSummary Objective: Despite CD4þ count restoration and viral load suppression with antire-
troviral therapy (ART), HIV-infected children remain at increased risk of life-threatening infec-
tions including invasive pneumococcal disease (IPD). We therefore investigated whether
persistent susceptibility to IPD following ART is associated with incomplete recovery of B-cell
function.
Methods: 41 HIV-infected Malawian children commencing ART were followed-up for a 1 year
period during which time blood samples were collected at 0, 3, 6 and 12 months for compre-
hensive immunophenotyping and pneumomococcal-specific Memory B-cell Enzyme-Linked Im-
munospot assays. In addition, nasopharyngeal swab samples were cultured to determine
pneumococcal carriage rates.
Results: Normalization of major lymphocyte subsets such as CD4þ percentages was evident
following 3 months of ART. The proportions of mature na€ıve B cells (CD19þ CD10 CD27
CD21hi) and resting memory B cells (CD19þ CD27þ CD21hi) increased and apoptosis-prone
mature activated B cells (CD19þ CD21lo CD10) decreased markedly by 12 months. However,
in the context of high nasopharyngeal pneumococcal carriage rates (83%), restoration of pneu-
mococcal protein antigen-specific B-cell memory was more delayed.linical Science and Cellular and Molecular Medicine, Level 6, UBH Education Centre, Upper Maudlin St,
: þ44 (0) 117 342 0172.
.ac.uk (A. Finn).
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Pneumococcal immunity during ART in children 617Conclusions: These data show that, in chronically HIV-infected children receiving ART,
improvement in B-cell memory profiles and function is slower than CD4þ T-cells. This supports
early initiation of ART and informs research into optimal timing of immunization with pneumo-
coccal vaccines.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Associat ion. This is an open access art icle under the CC BY l icense (http://
creativecommons.org/licenses/by/3.0/).Introduction
Streptococcus pneumoniae is a leading cause of infectious
death and hospitalization in HIV-infected adults and children
in most African countries.1,2 Antiretroviral therapy (ART)
leads to a reduction in the incidence of invasive pneumo-
coccal disease (IPD) but the risk remains high.3e6 It is widely
proposed that defective T-cell mediated immunity may be
responsible for this disease burden,7e9 however, we have
recently shown that compared to healthy uninfected chil-
dren, even minimally symptomatic HIV-infected individuals
with preservedCD4þ percentage have an overrepresentation
of mature activated B cells, suggestive of immune activation
and apoptosis, and low numbers of pneumococcal protein
antigenespecificmemory B cells.10 For at least two decades,
the peripheral blood CD4þ T cell count or percentage in
young children has been used as a correlate of HIV disease
progression both as an indicator for the commencement of
ART and to monitor its effectiveness when used.11,12 Effec-
tive treatment with ART leads to normalization of the CD4þ
T cell count in blood associated with reduction in levels of
inflammation, redistribution of T cells between tissues and
blood, decrease in cell turn over and increase in thymic pro-
ductivity and therefore CD4þ T-cell function.13e17 Moir and
colleagues have reported that despite adequate CD4þ count
recovery with ART, chronically infected adults have poor B
cell memory functional profiles in response to HIV and non-
HIV antigens when compared to individuals receiving ART
with more recent infection.18 We therefore hypothesized
that the persistent susceptibility to IPD seen in African chil-
dren receiving ART may be explained by poor recovery of B-
cell function and consequent delay in the re-establishment
of natural immunity to S. pneumoniae.
Accordingly we prospectively investigated children with
vertically acquired HIV infection commencing ART in Malawi
where there is a high burden of IPD.19 We demonstrate that
normalization of the circulating B cell phenotype occurs
rapidly following the initiation of ART but that, in the
context of high nasopharyngeal pneumococcal carriage
rates, reconstitution of pneumococcal protein antigen-
specific B cell memory is slower.Patients, materials and methods
Study participants
Following written informed consent from parents or guard-
ians, 45 HIV-infected children eligible to commence ART
according to the Malawi National ART program guidelines
operating at the time of enrollment, based either on clinical
criteria (WHO pediatric stage 3 or 4) or on low CD4þ count orpercentage20 were recruited at Queen Elizabeth Central Hos-
pital (Blantyre, Malawi), a large district and tertiary referral
hospital. A maximum of 5 ml whole blood and a nasopharyn-
geal swab samplewere collected from each study participant
on enrollment. In order to exclude malaria as a confounding
factor in the immunological assays, all children were tested
for malaria by microscopic examination of blood films. Chil-
drenweremonitored for a 1 yearperiod followingcommence-
ment of ART, duringwhich timeblood sampleswere collected
at 0, 3, 6 and 12 months, while nasopharyngeal swab samples
were collectedmonthly for the first 6months, and then every
2 months thereafter. None of the participants received any
pneumococcal vaccine before or during the study. This study
complies with relevant guidelines and institutional practices
of the Malawi-Liverpool Wellcome Trust Clinical Research
Programme and the University of Malawi College of Medicine
and was approved by the College of Medicine Research Ethics
Committee (P.11/07/591).
Thirty-seven HIV-uninfected controls within the same
age range undergoing elective surgery at the same hospital
were recruited as part of a separate contemporaneous
study reported elsewhere.10 The median values for pneu-
mococcal carriage and major phenotypic parameters,
from these children were used for comparative purposes.
Carriage study and bacterial culture
Nasopharyngeal samples were collected from study partic-
ipants using a swab (Medical wire) held by the shaft with
the tip inserted into the anterior nares and the medial nasal
wall carefully followed till resistance was felt. The swab
was then rotated through 180 on its long axis to ensure
good mucosal contact and withdrawn. Swabs were inocu-
lated into 1.5 ml skim milk-tryptone-glucose-glycerin broth
(STGG) and frozen.21 After storage and thawing, 50 ml of
broth was subsequently inoculated onto sheep blood agar
containing 5 mg/ml gentamicin. S. pneumoniae was identi-
fied by alpha hemolysis, colony morphology, bile salt solubi-
lity and optochin sensitivity.22
Immunophenotyping
The proportions and absolute numbers of B and T cells were
estimated in EDTA whole blood samples by flow cytometry
using the following antibodies: fluorescein isothiocyanate
(FITC)-labeled anti-CD19 & anti-CD21; phycoerythrin (PE)-
labeled anti-CD8, anti-CD27 & anti-IgD; peridinin chloro-
phyll protein (PerCP)-labeled CD3 & anti-CD19; allophyco-
cyanin (APC)-labeled anti-CD4, anti-CD10 & anti-CD27. All
antibodies used in flow cytometry assays were obtained
from BD Biosciences Ltd, with the exception of anti-CD21
(Beckman Coulter). B-cell subtypes were characterized
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leagues.18,23 Whole blood was incubated with respective
antibodies for 20 min at room temperature in the dark.
The red blood cells were lysed for 30 min using 1x lysis so-
lution (BD). The white blood cells were then pelleted by
centrifugation (450 g, 30 min, 25 C), washed in phosphate
buffered saline (PBS) supplemented with 0.5% bovine serum
albumin (Sigma) and fixed with 2% paraformaldehyde
(Sigma) before acquisition on a flow cytometer. At least
100,000 events were acquired within the lymphocyte gate
using CellQuest Pro software on a four-color flow cytometer
(BD FACSCalibur, BD Biosciences) or the Summit software
version 4.3 on a CyAn ADP (Beckman Coulter). Lymphocytes
were gated using forward and side scatter characteristics.
Results were analyzed using FlowJo software version 7.2.2
(Tree Star Inc., San Carlos, CA).Memory B cell Enzyme-Linked Immunospot
(ELISPOT) assay
Polyclonal stimulation was used to induce differentiation of
memory B cells into antibody secreting cells (ASC) in vitro.24
Pneumococcal specific ASC were then enumerated using an
ELISPOT assay. Briefly, peripheral blood mononuclear cells
(PBMC) were isolated by density gradient centrifugation us-
ing Lymphoprep (Axis Shield plc), resuspended in complete
RPMI medium (RPMI-1640 supplemented with 10 mM HEPES,
100 U/ml Penicillin, 0.1 mg/ml streptomycin and 2 mM L-
glutamine) containing 10% fetal calf serum, plated at
1  106 cells/ml in 2 ml volumes per well in 24-well plates
(Appleton woods). Freshly isolated PBMC were cultured for
6 days at 37 C in the presence of a combination of 1/
100,000 standardized pansorbin cells (heat-killed,
formalin-fixed Staphylococcus aureus, Cowan 1 strain;
SAC), 1 mg/ml phosphothiolated CpG oligodeoxynucleotide
2006 (CpG DNA) and 1/1000 pokeweed mitogen extract
(PWM). Cells were then harvested and plated at 4  105
cells/well on 96-well multiscreen plates (Millipore) pre-
coated with a pneumococcal protein antigen (1.5 mg/ml
Choline binding protein A (CbpA), 2 mg/ml Pneumococcal
surface protein A (PspA), 2 mg/ml Pneumolysin (Ply) or
2 mg/ml Pneumococcal surface antigen A (PsaA); all gener-
ated as previously described).25 Of the many pneumococcal
secreted or surface-expressed proteins, including LytC,
PcsB, that have been identified as potential vaccine anti-
gens,26e29 work described here was limited to only 4 anti-
gens due to sample constraints. These protein antigens
were chosen because they are well characterized as playing
a role in the pathogenesis of pneumococcal disease and
demonstrated to be protective against carriage and/or inva-
sive disease in humans and/or animal models.30e33 Knowl-
edge gained from these 4 protein antigens may be
applicable to other novel protein vaccine candidates, as
most of these protein antigens are fairly conserved among
all pneumococcal isolates. A cocktail of 10 ug/ml tuberculin
purified protein derivative (PPD; Statens Serum Ins.), 5 ug/
ml purified tetanus toxoid (Merck Biosciences) and 1 ug/ml
inactivated split virion influenza vaccine (Flu; Aventis Pas-
teur MSD) was used as a positive control and PBS alone as a
negative control. As PBS generated very few spots, back-
ground was not subtracted. As the total number of cellsrecovered from each blood sample varied, it was not always
possible to include all antigens in every assay. ASC were de-
tected by incubation with IgG secondary antibody (Sigma)
conjugated to alkaline phosphatase for at least 6 h prior to
development with an alkaline phosphatase substrate kit
(Bio-Rad). ASC were counted using an AID ELISPOT reader
and analysis software version 4.0 (AID Strasburg, Germany).
Statistics
Data were expressed as medians and interquartile ranges
(IQR). Comparisons were made using Friedman’s test to
evaluate the effect of ART across all time points (i.e. at
baseline and all 3 follow-up times). Statistical analysis and
graphical presentations were done using Stata 10 and Graph-
Pad Prism software (version 4.0). Differences after compar-
isons were considered statistically significant if P < 0.05.
Results
Baseline characteristics of the study participants
Of the 45 children recruited, 2 died, 1 moved away from
Blantyre and 1 withdrew from the study. These 4 children
were excluded from subsequent analysis and 41 HIV-infected
children with median age 92 months at recruitment (IQR,
63e132 months) were included. None of these 41 children
was malaria parasitemic at enrollment, all received cotri-
moxazole prophylaxis and none were febrile at any of the
follow-up visits. 18/41 (44%) were females and 23/40 (58%)
had S. pneumoniae detected by culture of a nasopharyngeal
swab obtained at enrollment. Pneumococcal carriage rates
varied between 58 and 92% throughout the course of the
study and the rate was 83% after 12 months of ART. The car-
riage rate in healthy controls with median age 92 months
(IQR, 54e132 months) was 46%.10
Changes in lymphocyte subsets
As expected, both absolute and percentage CD4þ T cell
counts rose significantly (P < 0.0001) following initiation of
ARTover the 12 months of the study. While on average, rises
in absolute counts were most obvious during the first 3
months, rises in percentages were more progressive over
the whole observation period although in neither case did
they reach median values seen in HIV-uninfected controls
(Fig. 1A and D). In contrast, no statistically significant trends
in absolute CD8þ T cell and CD19þ B cell counts were seen
over the same period (Fig. 1B and C). Values for CD8þ T cells
remained above those seen in uninfected controls showing
some apparent trend towards these normal values (Fig. 1B
and E) but median CD19þ B cell values remained consistently
lower than control values (Fig. 1C and F).
Changes in B cell subsets
Extending our recent report of an apoptosis-prone pheno-
type in HIV-infected children,10 we measured trends in
circulating B cell subsets during 12 months’ ART and
observed increases in proportions of both mature na€ıve
Figure 1 Progressive changes in major lymphocyte subsets of HIV-infected Malawian children over the course of 12 months’
antiretroviral therapy (ART). Absolute numbers of circulating (A) CD4þ T cells (B) CD8þ T cells and (C) CD19þ B cells; proportions of
(D) CD4þ T cells (E) CD8þ T cells and (F) CD19þ B cells measured using flow cytometry. Horizontal bars in AeF represent median
values. The broken horizontal lines in AeF represent median values in HIV-uninfected controls recruited as part of separate
contemporaneous study reported elsewhere and interquartile range for these controls have been incorporated in the y-axis.10 Com-
parisons were made using Friedman’s test to evaluate the effect of ART across all time points.
Figure 2 Increase in mature na€ıve & resting memory B cells and reduction of apoptosis prone mature activated B cells in HIV-
infected children following initiation of antiretroviral therapy (ART). Percentages of (A) mature na€ıve B cells (CD19þ CD10
CD27 CD21hi) (B) resting memory B cells (CD19þ CD27þ CD21hi) (C) mature activated B cells (CD19þ CD21lo CD10) (D) immature
transitional B cells (CD19þ CD10þ CD27) measured using flow cytometry in HIV-infected children on ART over 12 months. Horizon-
tal bars in AeD represent median values. The broken horizontal lines in AeD represent median values in HIV-uninfected controls
recruited as part of separate contemporaneous study reported elsewhere and interquartile range for these controls have been
incorporated in the y-axis.10 Comparisons were made using Friedman’s test to evaluate the effect of ART across all time points.
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Figure 3 Pneumococcal protein antigen specific IgG memory B cells increase after 12 months’ antiretroviral therapy (ART) in
HIV-infected Malawian children. Using an enzyme-linked immunospot (ELISPOT) assay, following the expansion of memory B cells
with a cocktail of mitogens (standardized pansorbin cells, pokeweed mitogen extract and phosphothiolated CpG oligodeoxynucleo-
tide 2006) for six days, (A) Choline binding protein A (CbpA), (B) Pneumococcal surface protein A (PspA), (C) Pneumolysin (Ply), and
(D) Pneumococcal surface antigen A (PsaA) specific IgG antibody secreting cells (ASCs) were enumerated in HIV-infected children
on ART. Memory B cell responses were expressed as numbers of antibody secreting cells (ASCs) per million cultured peripheral blood
mononuclear cells (PBMCs) seeded on the ELISPOT well. Each dot represents an average of test wells performed in triplicate. Hor-
izontal bars represent median values. The broken horizontal lines in AeC represent median values in HIV-uninfected controls re-
cruited as part of separate contemporaneous study reported elsewhere.10 The interquartile range for these controls has been
incorporated in the y-axis except the upper quartile band for CbpA specific memory B cells of 44.2 that was not incorporated owing
to axis break. PsaA specific memory B cells were not measured in the HIV-uninfected cohort. Comparisons were made using Fried-
man’s test to evaluate the effect of ART across all time points.
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(CD19þ CD27þ CD21hi) (P < 0.0001, P Z 0.04) which
occurred largely over the first 3 months and to levels, in
the former subset, that were higher than those seen in un-
infected controls while in the latter they remained below
normal median values (Fig. 2AeB). There were correspond-
ing falls in proportions of apoptosis-prone mature activated
(CD19þ CD21lo CD10) B cells (P < 0.0001) to levels seen in
uninfected controls (Fig. 2C). However, no significant or
consistent trends in numbers of apoptosis-prone immature
transitional (CD19þ CD10þ CD27) B cell percentages were
observed (Fig. 2D).Changes in pneumococcal protein antigen specific
immunoglobulin G memory B cells
In contrast to total B cell subsets, recovery in numbers of
circulating memory B cells specific for four pneumococcal
antigens (Choline binding protein A (CbpA), Pneumococcal
surface protein A (PspA), Pneumolysin (Ply) and Pneumo-
coccal surface antigen A (PsaA)) only became apparent
during the latter part of the 12 month observation period
(P Z 0.007, P Z 0.02, P Z 0.02, P Z 0.001 respectively(Fig. 3)). Median values approached those seen in unin-
fected controls by 12 months for two of the three antigens
for which control data were available (Fig. 3).Discussion
The reversal of the immunodeficiency, in particular T cell
function, associated with untreated HIV and following the
initiation of ART is well described.5,18,23,34e36 The impact of
ART on recovery of B cell function has received less atten-
tion. Here we describe reconstitution of B lymphocyte sub-
sets in juxtaposition with reappearance of pneumococcus-
specific memory B cells in Malawian children.
Alongside normalization of CD4 and CD8 subsets, correc-
tion of B cell subset counts, including mature na€ıve, resting
memory and apoptosis-prone mature activated B cells had
largely occurred by 3 months after commencement of ART.
In contrast and in the context of prevalent nasopharyngeal
pneumococcal carriage throughout the study, circulating
pneumococcal protein antigen-specific memory B cells only
became more abundant towards the end of the 12-month
study period suggesting that antigen-specific B cell memory
function may lag behind other indices of B cell recovery.
Pneumococcal immunity during ART in children 621Although a switch from short-lived apoptosis prone B
cells to longer-lived na€ıve and resting memory B cells was
seen relatively early after initiation of ART, there were no
significant changes observed in the percentages and abso-
lute numbers of total CD19þ B cells during ART in this
cohort during the 12 months of observation. Some previous
studies in children have shown no changes in total CD19þ B
cells during ART37 while other studies in both adults and
children have shown rises.18,38e40 There are numerous fac-
tors that may differ between these samples which could
have contributed to these discordant findings but the
most immediate apparent need is to follow these trends
over a longer observation period.
We have previously demonstrated acquisition of pneumo-
coccal protein-specific Tcell and B cell immunity in both low
carriage and high carriage populations.10,41e45 This naturally
acquired immunity may occur as a result of multiple immu-
nizing carriage events to a range of pneumococcal proteins
expressed at the mucosal surface.46 In African children,
pneumococcal nasopharyngeal carriage occurs very early in
life and reaches very high rates47 and, as in this study, car-
riage rates may be higher among those with HIV infection.48
In this context, we have recently shown that even in mini-
mally symptomatic HIV-infected children, pneumococcal
protein antigen-specific memory B-cell numbers are low
compared with HIV-uninfected children.10 The delayed re-
covery in pneumococcal antigen specific B cell memory after
institution of ART that we describe here may indicate that
these HIV-infected children remain both more vulnerable
to invasive pneumococcal disease and to prolonged or higher
density carriage. Understanding more clearly how B cell im-
mune reconstitution relates to pneumococcal colonization
will be important in countries such as Malawi with high HIV
prevalence and where pneumococcal conjugate vaccine
(PCV) has recently been introduced into the routine infant
immunization schedule, particularly since the effectiveness
of these vaccines is to a great extent mediated by effects on
carriage and transmission.49
Many of the children reported here were commenced on
ART with a low percentage CD4 nadir (Fig. 1A). It is possible
that the delayed and incomplete restoration of antigen-
specific B cell function we observed would have been
ameliorated by earlier initiation of ART.18,50,51 This ques-
tion has begun to be tackled programmatically as the
thresholds for initiating ART are lowered but merits further
investigation if vaccines are to be targeted effectively.
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